Results for tag: "Macular Telangiectasia Drug"

Macular Telangiectasia (MacTel) is a rare, progressive eye disorder that affects the macula, the central part of the retina responsible for sharp, central vision. It is characterized by the formation of abnormal blood vessels in the macula, which can lead to vision loss. Treatment for MacTel is limited and includes laser therapy, photodynamic therapy, and anti-VEGF injections. Optical Disorders Drugs are medications used to treat a variety of eye diseases, including MacTel. These drugs are designed to reduce the progression of the disease and improve vision. Common Optical Disorders Drugs used to treat MacTel include anti-VEGF drugs, such as ranibizumab and aflibercept, and corticosteroids, such as dexamethasone. The Macular Telangiectasia Drug market is a rapidly growing segment of the Optical Disorders Drugs market. It is driven by the increasing prevalence of MacTel and the need for effective treatments. Companies in the Macular Telangiectasia Drug market include Regeneron Pharmaceuticals, Novartis, Allergan, and Roche. Show Less Read more